<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354246</url>
  </required_header>
  <id_info>
    <org_study_id>CPG-02-101</org_study_id>
    <nct_id>NCT04354246</nct_id>
  </id_info>
  <brief_title>COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Compugen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Compugen Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 open label sequential dose escalation and cohort expansion study evaluating the&#xD;
      safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in&#xD;
      combination with COM701 in subjects with advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of COM902 monotherapy and in combination with COM701.</measure>
    <time_frame>DLT evaluation window in the 1st cycle (21 Days).</time_frame>
    <description>Incidence of subjects with Adverse Events (AEs) as per CTCAE v5.0 and Dose-Limiting Toxicities (DLTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the maximum tolerated dose (MTD) and/or recommended dose for expansion of COM902 monotherapy and in combination with COM701.</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of a dose of COM902 monotherapy and in combination with COM701 that is well tolerated by subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of COM902 as monotherapy and in combination with COM701.</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of parameters of COM902 monotherapy or in combination with COM701 exposure such as Maximum Plasma Concentration [Cmax]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize immunogenicity of COM902 monotherapy and in combination with COM701.</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of anti drug antibody to COM902 (monotherapy) or COM902, COM701 when administered in combination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of the preliminary antitumor activity of COM902 as monotherapy and in combination with COM701.</measure>
    <time_frame>24 months.</time_frame>
    <description>An assessment of preliminary antitumor activity eg ORR with COM902 monotherapy and COM902 in combination with COM701.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Multiple Myeloma</condition>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>COM902 monotherapy dose escalation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COM902 monotherapy cohort expansion at RDFE.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COM902 + COM701 combination cohort expansion both at RDFE.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose escalation: COM902 monotherapy.</intervention_name>
    <description>COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.</description>
    <arm_group_label>COM902 monotherapy dose escalation.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)</intervention_name>
    <description>Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.</description>
    <arm_group_label>Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort expansion: COM902 (RDFE) monotherapy.</intervention_name>
    <description>COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.</description>
    <arm_group_label>COM902 monotherapy cohort expansion at RDFE.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort expansion: COM902 in combination with COM701 (both at the RDFE).</intervention_name>
    <description>COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.</description>
    <arm_group_label>COM902 + COM701 combination cohort expansion both at RDFE.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor)&#xD;
             who must have exhausted all available standard therapy; or not a candidate for&#xD;
             standard therapy.&#xD;
&#xD;
          -  Subject is able to provide written, informed consent before initiation of any study&#xD;
             related procedures, and is able, in the opinion of the investigator, to comply with&#xD;
             all the requirements of the study.&#xD;
&#xD;
          -  Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a TIGIT inhibitor.&#xD;
&#xD;
          -  Symptomatic interstitial lung disease or inflammatory pneumonitis.&#xD;
&#xD;
          -  History of immune-related events that required immunotherapy treatment&#xD;
             discontinuation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lead COM902 ClinInfo</last_name>
    <phone>â€ª+1 415 373 0781</phone>
    <email>COM902-001@cgen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Backup COM902 ClinInfo</last_name>
    <phone>+1 415 373 0781</phone>
    <email>COM902-001@cgen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>START Midwest.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tennessee WEST Cancer Center.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director.</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The START Center for Cancer Care.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIGIT antibody</keyword>
  <keyword>PVRIG antibody</keyword>
  <keyword>COM701</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

